Tuesday, November 24, 2009, 4:41AM AEST - The Australian Stockmarket opens in 5 hours and 19 minutes.
To create a watchlist or portfolio of shares, Register

Genzyme Corp. (GENZ)

4:26AM AEST: 50.47 USD  Up 0.42 (0.84%)  
 MORE ON GENZ 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 Genzyme Corporation (NasdaqNM:GENZ) Delayed quote dataEdit
Last Trade:50.47 USD
Trade Time: 4:26AM AEST
Change:Up 0.42 (0.84%)
Prev Close:50.05
Open:50.25
Bid:50.47 x 900
Ask:50.47 x 100
1y Target Est:58.61
Day's Range:50.00 - 50.90
52wk Range:47.09 - 73.75
Volume:1,372,409
Avg Vol (3m):3,520,820
Market Cap:13.39B
P/E (ttm):28.77
EPS (ttm):1.75
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add GENZ to Portfolio   Download Data

 HEADLINES 
Icahn Makes Big Moves in Healthcare Stocks
Indie Research (Tue 1:13AM)
Wall Street's 10 Favorite Stocks Right Now
at Motley Fool (Sat, Nov 21)
Uncertainty Breeds Opportunity in Specialty Pharma Stock Pick From Piper Jaffray Senior Research Analyst
Wall Street Transcript (Sat, Nov 21)
Biotech Stock Mailbag: FDA Playbook
at TheStreet.com (Fri, Nov 20)
Now's a Great Time to Invest -- So Don't Blow It Like This
at Motley Fool (Fri, Nov 20)
This Stock Is a Train Wreck
at Motley Fool (Fri, Nov 20)
Genzyme: Analysts' Upgrades, Downgrades
at TheStreet.com (Fri, Nov 20)
Genzyme's Problems Continue
Zacks.com (Fri, Nov 20)
Zacks #5 Rank Additions for Thursday
Zacks.com (Thu, Nov 19)
Drug Lowers Cholesterol; Stock Follows
at Motley Fool (Thu, Nov 19)
Genzyme Drops Kidney-Drug Plans Amid Pileup of Bad News
at The Wall Street Journal Online (Thu, Nov 19)
UPDATE - Genzyme negative news continues; stops drug trial
at Reuters (Thu, Nov 19)
Another Genzyme Drug Goes Kaboom: BioBuzz
at TheStreet.com (Thu, Nov 19)
More Headlines for GENZ...

 ANALYST 
EPS Est (next year) (Dec-09) :2.27
EPS Est (in 2 years) (Dec-10) :3.72
Avg Rec (current)*:2.3
PEG Ratio:1.01
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Genzyme Corporation operates as a biotechnology company worldwide. The company’s Genetic Diseases segment manufactures and distributes therapeutic products, including Cerezyme as an enzyme replacement therapy for the treatment of Type 1 and T...

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
Latest News7 Indices